6:03 AM ET
10-Q
Financial Results
InMed Pharmaceuticals Q1 2026 Results: Net Loss of $2.33M, Loss Widens
InMed Pharmaceuticals Inc. reported its financial results for the quarter ended September 30, 2026, highlighting ongoing research and development expenses related to its cannabinoid-based pipeline. The company continues to manage its cash position to fund clinical trials and proprietary manufacturing technology development.
- Key figure
- Net loss $2.33M